Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 4/20 | 0.33 |
| ▸ | KRAS | P01116 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.32 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | RXRB | P28702 | 1/20 | 0.31 |
| ▸ | RXRG | P48443 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5847254 | 0.80 | MAP3K8 (0.36) | KRASMAP3K8 | |
| SCHEMBL6508762 | 0.77 | KRAS (0.33) | ATRPRMT5WDR77KRASFGFR1 | |
| SCHEMBL6508905 | 0.73 | ABL1 (0.32) | ATRKRASFGFR1DDR2RXRA | |
| SCHEMBL6505280 | 0.72 | HTR2C (0.32) | KRASMAP3K8RXRARXRBRXRG | |
| SCHEMBL5846701 | 0.71 | CDK1 (0.43) | MAP3K8 | |
| SCHEMBL6503321 | 0.71 | FGFR1 (0.33) | ATRCDK9FGFR1DDR2RXRA | |
| SCHEMBL6504036 | 0.71 | MAP3K8 (0.33) | ATRKRASMAP3K8RXRARXRB | |
| SCHEMBL6508663 | 0.71 | MAP3K8 (0.39) | BRD4ATRKRASFGFR1DDR2 | |
| SCHEMBL6501988 | 0.69 | HTR2C (0.32) | — | |
| SCHEMBL6502580 | 0.68 | KRAS (0.33) | ATRKRASMAP3K8RXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060142345-A1 | 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2006-06-29 | — | — | US | disclosed |
| US-7008953-B2 | 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. (US) | 2006-03-07 | — | — | US | disclosed |
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | AGOURON PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026960-A1 | 3, 5 disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDKL3 | BRD4 201/4885ATR 1196/4885PRMT5 547/4885 |
| US-20060142345-A1 | 3,5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation | CDK3, CDK4, CDKL3 | BRD4 201/4885ATR 1196/4885PRMT5 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.